Compositions and methods for the treatment of inflammation and lipid disorders

Patent metadata

Field	Value
Publication number	US-9670153-B2
Application number	US-201314533112-A
Country	US
Kind code	B2
Filing date	Aug 17, 2013
Priority date	Sep 8, 2012
Publication date	Jun 6, 2017
Grant date	Jun 6, 2017

Abstract

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammation and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hypertriglyceridemia, steatohepatitis, cystinosis and inflammatory diseases.

First claim

The invention claimed is:

1. A compound represented by:

and pharmaceutically acceptable salts, hydrates, solvates, enantiomers, and stereoisomers thereof, wherein:
R 2 represents

 and
wherein each a is independently 2, 3, or 7; and
wherein each b is independently 3, 5, or 6.

2. A compound represented by:

and pharmaceutically acceptable salts, hydrates, solvates, enantiomers, and stereoisomers thereof, wherein:
R 2 represents

 and
wherein each b is independently 3, 5 or 6;
wherein each e is independently 1, 2 or 6; and
wherein each c and d are each independently H, D, —OH, —OD, C 1 -C 6 -alkyl, —NH 2 or —COCH 3 .

3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 3 , further comprising a molecular conjugate of (R)-2,4-dihydroxy-N-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-3,3-dimethylbutanamide and carboxylic acid compounds selected from a group consisting of eicosapentaenoic acid and docosahexaenoic acid.

6. The pharmaceutical composition of claim 5 , wherein the carboxylic acid compound is eicosapentaenoic acid.

7. The pharmaceutical composition of claim 5 , wherein the carboxylic acid compound is docosahexaenoic acid.

8. The pharmaceutical composition of claim 4 , further comprising a molecular conjugate of (R)-2,4-dihydroxy-N-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-3,3-dimethylbutanamide carboxylic acid compounds selected from a group consisting of eicosapentaenoic acid and docosahexaenoic acid.

9. The pharmaceutical composition of claim 8 , wherein the carboxylic acid compound is eicosapentaenoic acid.

10. The pharmaceutical composition of claim 8 , wherein the carboxylic acid compound is docosahexaenoic acid.

Assignees

• Cellix Bio Private Ltd
• Cellix Bio Private Ltd

Inventors

• Kandula Mahesh

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61K31/16

  Amides, e.g. hydroxamic acids · CPC title